Literature DB >> 29079288

Predictors of sorafenib benefit in patients with hepatocellular carcinoma.

Richard Jackson1, Eftychia Psarelli1, Sarah Berhane2, Philip J Johnson3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 29079288     DOI： 10.1016/j.jhep.2017.09.028

Source DB:  PubMed          Journal:  J Hepatol        ISSN： 0168-8278            Impact factor:   25.083


× No keyword cloud information.
  3 in total

1.  Identification of Functional MKK3/6 and MEK1/2 Homologs from Echinococcus granulosus and Investigation of Protoscolecidal Activity of Mitogen-Activated Protein Kinase Signaling Pathway Inhibitors In Vitro and In Vivo.

Authors:  Chuanshan Zhang; Jing Li; Tuerganaili Aji; Liang Li; Xiaojuan Bi; Ning Yang; Zhide Li; Hui Wang; Rui Mao; Guodong Lü; Yingmei Shao; Dominique A Vuitton; Hao Wen; Renyong Lin
Journal:  Antimicrob Agents Chemother       Date:  2018-12-21       Impact factor: 5.191

2.  Exploratory Analysis to Identify Candidates Benefitting from Combination Therapy of Transarterial Chemoembolization and Sorafenib for First-Line Treatment of Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Observational Study.

Authors:  Zhexuan Wang; Enxin Wang; Wei Bai; Dongdong Xia; Rong Ding; Jiaping Li; Qiuhe Wang; Lei Liu; Junhui Sun; Wei Mu; Hui Zhao; Xingnan Pan; Guoliang Shao; Xiaoli Zhu; Guowen Yin; Haibin Shi; Jianbing Wu; Zhengyu Lin; Shufa Yang; Jueshi Liu; Wenhui Wang; Xu Zhu; Yong Lv; Jing Li; Hui Chen; Wenjun Wang; Kai Li; Xulong Yuan; Tanlei Yu; Jie Yuan; Xiaomei Li; Jing Niu; Zhanxin Yin; Jielai Xia; Daiming Fan; Guohong Han
Journal:  Liver Cancer       Date:  2020-02-19       Impact factor: 11.740

3.  Clinical aspects and treatment of hepatocellular carcinoma in north-eastern Poland.

Authors:  Tadeusz Wojciech Łapiński; Aleksandr Tarasik; Marcin Januszkiewicz; Robert Flisiak
Journal:  Clin Exp Hepatol       Date:  2021-03-25
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.